Barclays PLC Invests $3.34 Million in Anavex Life Sciences Corp. (NASDAQ:AVXL)
Posted by Stuart Ham on Jun 10th, 2022
Anavex Life Sciences logoBarclays PLC bought a new position in Anavex Life Sciences Corp. (NASDAQ:AVXL – Get Rating) in the 4th quarter, HoldingsChannel.com reports. The firm bought 192,354 shares of the biotechnology company’s stock, valued at approximately $3,335,000.
A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. Gotham Asset Management LLC bought a new position in Anavex Life Sciences during the fourth quarter valued at about $307,000. Invesco Ltd. grew its position in Anavex Life Sciences by 1,091.7% during the fourth quarter. Invesco Ltd. now owns 435,239 shares of the biotechnology company’s stock valued at $7,548,000 after buying an additional 398,718 shares during the period. Geode Capital Management LLC grew its position in Anavex Life Sciences by 8.3% during the fourth quarter. Geode Capital Management LLC now owns 1,297,371 shares of the biotechnology company’s stock valued at $22,496,000 after buying an additional 99,262 shares during the period. O Shaughnessy Asset Management LLC grew its position in Anavex Life Sciences by 161.6% during the fourth quarter. O Shaughnessy Asset Management LLC now owns 11,332 shares of the biotechnology company’s stock valued at $196,000 after buying an additional 7,000 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its position in Anavex Life Sciences by 3.3% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 515,840 shares of the biotechnology company’s stock valued at $8,945,000 after buying an additional 16,634 shares during the period. Institutional investors own 29.01% of the company’s stock.
Get Anavex Life Sciences alerts:
In other news, Director Athanasios Skarpelos sold 50,000 shares of the stock in a transaction dated Wednesday, May 25th. The shares were sold at an average price of $9.06, for a total value of $453,000.00. Following the sale, the director now directly owns 1,306,458 shares of the company’s stock, valued at $11,836,509.48. The sale was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 11.00% of the company’s stock.
AVXL has been the subject of several research reports. HC Wainwright restated a “buy” rating and set a $42.00 price target on shares of Anavex Life Sciences in a research report on Wednesday, March 16th. Zacks Investment Research raised shares of Anavex Life Sciences from a “hold” rating to a “buy” rating and set a $10.00 price objective on the stock in a report on Wednesday, May 25th. Finally, StockNews.com began coverage on shares of Anavex Life Sciences in a report on Thursday, March 31st. They set a “sell” rating on the stock. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $32.67.
NASDAQ AVXL opened at $8.54 on Friday. The company has a market cap of $661.07 million, a PE ratio of -14.98 and a beta of 0.92. Anavex Life Sciences Corp. has a 52 week low of $7.13 and a 52 week high of $31.50. The firm’s 50-day simple moving average is $9.63 and its two-hundred day simple moving average is $12.65.
Anavex Life Sciences (NASDAQ:AVXL – Get Rating) last announced its quarterly earnings results on Tuesday, May 10th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.03. During the same quarter in the previous year, the company earned ($0.12) earnings per share. As a group, equities research analysts expect that Anavex Life Sciences Corp. will post -0.85 EPS for the current fiscal year.
Anavex Life Sciences Profile (Get Rating)
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. |
